GLAUKOS Corp (GKOS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 13.09%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 13.09% | Share-based compensation / revenue. Period ending 2026-06-30. $80.22M ÷ $612.84M × 100 ≈ 13.09% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 612.84M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 80.22M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -193.36M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $612.84M | $80.22M | $-193.36M | (m) | (m) | 13.09% | (m) | (m) |
| 2026-03-31 | (m) | $551.35M | $69.38M | $-198.78M | (m) | (m) | 12.58% | (m) | (m) |
| 2025-12-31 | (m) | $507.44M | $63.22M | $-199.60M | (m) | (m) | 12.46% | (m) | (m) |
| 2025-09-30 | (m) | $469.82M | $59.23M | $-88.40M | (m) | (m) | 12.61% | (m) | (m) |
| 2025-06-30 | (m) | $432.95M | $58.73M | $-96.69M | (m) | (m) | 13.57% | (m) | (m) |
| 2025-03-31 | (m) | $404.52M | $52.03M | $-103.98M | (m) | (m) | 12.86% | (m) | (m) |
| 2024-12-31 | (m) | $383.48M | $50.21M | $-122.37M | (m) | (m) | 13.09% | (m) | (m) |
| 2024-09-30 | (m) | $360.35M | $49.88M | $-132.32M | (m) | (m) | 13.84% | (m) | (m) |
| 2024-06-30 | (m) | $341.73M | $45.95M | $-135.67M | (m) | (m) | 13.45% | (m) | (m) |
| 2024-03-31 | (m) | $326.43M | $44.51M | $-134.77M | $13.68M | (m) | 13.63% | -9.86× | Reported |
| 2023-12-31 | (m) | $314.71M | $43.53M | $-128.70M | $13.63M | (m) | 13.83% | -9.44× | Reported |
| 2023-09-30 | (m) | $303.57M | $42.23M | $-123.81M | $13.61M | (m) | 13.91% | -9.09× | Reported |
| 2023-06-30 | (m) | $296.79M | $41.16M | $-117.41M | $13.70M | (m) | 13.87% | -8.57× | Reported |
| 2023-03-31 | (m) | $289.08M | $41.82M | $-125.10M | $13.71M | (m) | 14.47% | -9.12× | Reported |
| 2022-12-31 | (m) | $282.86M | $38.56M | $-82.31M | $13.72M | (m) | 13.63% | -6.00× | Reported |
| 2022-09-30 | (m) | $284.88M | $34.10M | $-66.45M | $13.73M | (m) | 11.97% | -4.84× | Reported |
| 2022-06-30 | (m) | $288.32M | $30.88M | $-33.81M | $13.67M | (m) | 10.71% | -2.47× | Reported |
| 2022-03-31 | (m) | $293.72M | $28.32M | $-11.28M | $13.56M | (m) | 9.64% | -0.83× | Reported |
| 2021-12-31 | (m) | $294.01M | $30.15M | $-32.87M | $13.37M | (m) | 10.25% | -2.46× | Reported |
| 2021-09-30 | (m) | $294.00M | $31.66M | $-26.39M | (m) | (m) | 10.77% | (m) | (m) |
| 2021-06-30 | (m) | $284.13M | $35.14M | $-49.77M | (m) | (m) | 12.37% | (m) | (m) |
| 2021-03-31 | (m) | $237.59M | $38.05M | $-82.75M | (m) | (m) | 16.01% | (m) | (m) |
| 2020-12-31 | (m) | $224.96M | $46.48M | $-123.55M | $14.12M | (m) | 20.66% | -8.75× | Reported |
| 2020-09-30 | (m) | $217.57M | $50.20M | $-141.86M | (m) | (m) | 23.07% | (m) | (m) |
| 2020-06-30 | (m) | $211.25M | $49.09M | $-141.92M | (m) | (m) | 23.24% | (m) | (m) |
| 2020-03-31 | (m) | $238.29M | $46.44M | $-100.96M | (m) | (m) | 19.49% | (m) | (m) |
| 2019-12-31 | (m) | $236.98M | $36.39M | $-50.29M | $2.56M | (m) | 15.36% | -19.61× | Reported |
| 2019-09-30 | (m) | $225.21M | $30.59M | $-18.70M | (m) | (m) | 13.58% | (m) | (m) |
| 2019-06-30 | (m) | $210.61M | $29.22M | $-13.22M | (m) | (m) | 13.87% | (m) | (m) |
| 2019-03-31 | $52.70M | $195.17M | $27.43M | $-11.23M | (m) | 27.00% | 14.05% | (m) | (m) |
| 2018-12-31 | $49.68M | $181.28M | $25.70M | $-13.00M | (m) | 27.40% | 14.18% | (m) | (m) |
| 2018-09-30 | (m) | $168.85M | $23.98M | $-14.37M | (m) | (m) | 14.20% | (m) | (m) |
| 2018-06-30 | (m) | $165.36M | $21.52M | $-6.68M | (m) | (m) | 13.01% | (m) | (m) |
| 2018-03-31 | (m) | $163.48M | $19.79M | $-6.30M | (m) | (m) | 12.11% | (m) | (m) |
| 2017-12-31 | $38.91M | $159.25M | $17.59M | $-2.28M | (m) | 24.43% | 11.05% | (m) | (m) |
| 2017-09-30 | (m) | $150.78M | $15.32M | $-2.35M | (m) | (m) | 10.16% | (m) | (m) |
| 2017-06-30 | (m) | $139.94M | $13.26M | $-2.06M | (m) | (m) | 9.47% | (m) | (m) |
| 2017-03-31 | $31.10M | $127.21M | $10.57M | $3.92M | (m) | 24.45% | 8.31% | (m) | (m) |
| 2016-12-31 | $29.22M | $114.40M | $8.79M | $4.24M | (m) | 25.55% | 7.68% | (m) | (m) |
| 2016-09-30 | $28.12M | $101.50M | $7.67M | $1.77M | (m) | 27.70% | 7.56% | (m) | (m) |
| 2016-06-30 | $26.48M | $90.93M | $6.58M | $-987.00K | (m) | 29.13% | 7.23% | (m) | (m) |
| 2016-03-31 | $26.87M | $80.13M | $8.95M | $-8.49M | (m) | 33.53% | 11.17% | (m) | (m) |
| 2015-12-31 | $25.05M | $71.70M | $7.89M | $-10.30M | (m) | 34.93% | 11.00% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $20.06M | (m) | (m) | $-10.33M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $19.20M | $45.59M | $1.53M | $-13.17M | (m) | 42.13% | 3.36% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $15.51M | $20.95M | $1.35M | $-14.20M | (m) | 74.05% | 6.43% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |